Soricimed Wins Orphan Drug Status
Sackville, N.B.-based Soricimed Biopharma Inc., a clinical-stage pharmaceutical company developing peptide-based cancer therapeutics, has won a key regulatory approval from the Food and Drug Administration in the U.S.
The company said in a statement the FDA has granted orphan-drug designation to Soricmed’s flagship compound SOR-C13 for the treatment of ovarian cancer. Orphan drug status qualifies Soricimed for various development incentives, including tax credits and reduced filing fees for clinical trials undertaken in the U.S. If approved for commercialization by the FDA, SOR-C13 may